PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Par	perwork R	leduction A	ct of 199	5, no pe	rsons are n	equired to re	spond to a collection of	information	unless it cont	ains a valid Ol	/IB contr
							.Co	omplete	if Known		
Substitute for form 1449A/PTO					Appl	ication Number		09/699,13	31 10/709	5,448	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing	Date .		10/26/200	,		
					First	Named Inventor		Joseph L	. Witztum		
1	(use as m	nany sheets	as nece	ssary)		Grou	p Art Unit		Unknown	164	/
						Exan	niner Name		Unknown	LVCa	
Sheet		1	of		2	Attor	ney Docket Num	ber	6627-PA0	0045	
					U.S.	PATENT	DOCUMENTS				
	0.40	U.	S. Patent	t Docum	ent			_	Date	of Publication	of
Examiner nitials*	Cite No. ¹	Numi	per		nd Code ² if known)	Nam	ne of Patentee or Applic of Cited Document	ant	C	ited Document MM-DD-YYYY	
WC	1		5,33	0,910		Young e	t al.		(07-19-1994	
LY/C	2	5,460,947		Young e	t al.		1	10-24-1995			
	ļ	L		· '							
	-										
	<u> </u>		-								
	-	-			,,		·				
·	 										
						,					-
	<u> </u>					·		$\overline{}$		<u> </u>	
						·					
					FOREIG	N PATEN	T DOCUMENTS				\
		Foreign Patent Document							1		
examiner Initials*	Cite No. 1	Office ³	·	Number (if know		ind Code ⁵	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY		7*
LYC	3		wo	O 98/21581			Tsimikas e	al	05-22	-1998	
										-	
	_										

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

^{&#}x27;Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. 4Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of Information unless it contains a valid OMB control number.

						ired to respond to a collection of	omplete if Knov		,	
Substitute for	form 144	9B/PTO				Application Number	09/699	09/699,131 /0/705,448		
	INFORMATION DISCLOSURE					Filing Date	Octobe	r 26, 2000		
STA	ATEM	IENT BY	APPLI	CANT	Γ	First Named Inventor	Joseph	L. Witztum		
	(use a	s many sheets a	s necessary	()		Group Art Unit	Unknov	vn /64/		
				,		Examiner Name	Unknov	vn L/Caol	iC_	
Sheet			2	of	2	Attorney Docket Num	ber 6627-P	A0045		
	,		OTHER P	RIOR A	RT - NO	N PATENT LITERATURE D	OCUMENTS			
Examiner Initials*	Cite No.1					LETTERS), title of the article (who alog, etc.), date, page(s), volume- country where published.			T² '	
L/C	4	Hörkkö, S., oxidized pho LDL. J. Clin	ospholipic	ds: reco	gnition o	Antiphospholipid antibodie f cardiolipin by monoclonal 5.	s are directed aga antibodies to epit	inst epitopes of opes of oxidized	1	
	5	Generation	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. <i>Science</i> . 1989;246:1275-1281.							
	6	lipoproteins	Palinski, W., Hörkkö, S., Miller et al: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apo E-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. <i>J. Clin. Invest.</i> 1996 ;98:800-814.							
	7	Natural antil	Shaw, P.X., Hörkkö, S., Chang, M-K., Curtiss, L.K., Palinski, W., Silverman, G.J. and Witztum, J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotoc clearance, and protective immunity. <i>J. Clin. Invest.</i> 105:1731-40, 2000.					•		
	8	Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witzturn JL. Radiolabeled MDA2, an oxidation-specific, Mab, identifies native atherosclerotic lesions in vivo. <i>J Nucl Cardiol.</i> 1999;6:41-53.					···			
UC.	9	Wu CC, Cha hypercholes	ang SW, (sterolemic	Chen M rabbits	S, Lee Y . <i>Arterio</i> :	Ti. Early change of vascula scler Thromb Vasc Biol. 19	r permeability in 95;15:529-533.	·		
					<u> </u>		•			
			, ,						<u> </u>	
				····					-	
			· · · · · · · · · · · · · · · · · · ·	***··						
Examiner		Air	x.X.	(200	K_		Date Considered	12/23/05	····	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Hades the Department Bad without Aut of 1995, so nament on	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons an	e required to respond to a collection of information unless it contains a valid OMB control number
halib do for form 1440/DTO	Complete if Known

Subetitu	te for form 1449/	PTO			Complete if Known
/ Substitu	14 TO 16 TO			Application Number	09/699,131 10/705,448
INF	ORMATI	ON DIS	CLOSURE	Filing Date	10/26/2000
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Joseph L. Witztum
	(llon on mor	ıy sheets as n		Art Unit	1641
	(Ose as man	iy sh ou ts as n	ecessary)	Examiner Name	Lisa V. Cook
Sheet	1	of	1	Attorney Docket Number	6627-PA0045

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LVC	10	Libby, P. et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine, Vol. 8, No. 11, 1257-1262, Nov. 2002	
	11	Narula, J., et al. Strategic targeting of atherosclerotic lesions. Journal of Nuclear Cardiology, Part 1, pp. 81-90, Jan./Feb. 1999	
LYC	12	Strauss, H.W. Imaging of atherosclerosis – A worthy challenge. Journal of Nuclear Cardiology, Vol. 3, No. 3, pp. 278-280, May/June 1996	
		·	
·			

	1		
Examiner	O 2 N a Al	Date	
Signature	Giordor	Considered	12/23/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mplete if Known
Application Number	10/705,448
Filing Date	11/11/2003
First Named Inventor	WITZTUM et al
Art Unit	unknown 1641
Examiner Name	unknown Wcoci-
Attorney Docket Number	6627-P0045C

U. S. PATENT DOCUMENTS								
Examiner initials*	Cite No.¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
4/C.	1	^{US-} 5,330,910	7-19-1994	Young et al	whole document			
	2	^{US-} 5,460,947	10-24-1995	Young et al	whole document			
LYC	3	US- 6,375,925		Witztum et al	whole document			
		US-		·				
-		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-		,	·			
		US-						
		US-						
	 	US-						
		US-						
		US-						
		US-	†					
		US-						
		US-						

Examiner Initials*	Cite No.1	FORE Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	7
LYC	4	WO/98/21581	5-22-1998	Tsimikas et al	whole document	
HC-	5	WO 94/23302	10-13-1994	Selley	whole document	L
						L
						┝
					<u> </u>	₽

Examiner Date Signature Considered 12/23/05					
17290	Examiner Signature	Ofion X	(22)7	Date	12/23/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO			Complete if Known			
- Substitu	10 10 10 11 14-37 10			Application Number	10/705,448		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	11/11/2003		
STA	TEMENT	BY A	PPLICANT	First Named Inventor	WITZTUM et al		
	(Use as many st			Art Unit	unknown 1641		
	(Use as many sr	ieeus as r	lecessary)	Examiner Name	unknown L Cock		
Sheet	2	of	3	Attorney Docket Number	6627-P0045C		

			NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No.1			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
4/C	i	6	Hoorko S. Miller, E. Dudl E. et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids:recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized LDL. J. Clin. Invest.;1996:98; 815-825	
		7	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. Science . 1989;246:1275-1281	
		8	Palinski W. Horkko, S. Miller et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins for apo E-deficient mice. Demostration of epitopes of oxidezed LDL in human plasma. J.Clon.Invest 1996;98:800-814	
		9	Shaw P.X, Horkko, S. Chang, M-K Curtiss, L.K. Palinski, W. Silverman, G.J. and Witztum, J.L. Natural antibodies with T15 idiotype may act in atheosclerosis, apoptotoc clearance and protective immunity. J. Clin, Invest. 105:1731-40, 2000	
		10	Wu CC, Chang SW, Chen MS, Lee YT. Early change of vascular permeability in hypercholoesterloemic rabbits. Arterioscler Thomb Vasc Biol. 1995, 15-529-533	
		11	Libby P. et al. Stabilizing of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine. Vol 8, No. 11, 1257-1262-Nov. 2002	
		12 ·	Narula, J. et al. Strategic targeting of atherosclerotic lesions. Journal of Nucelar Cardiology, Part 1, pp. 81-90 Jan./Feb 1999	
		13	Strauss, H.W. Imaging of atheosclerosis-A worthy challenge. Journal of Nucelar Cardiology, Vol 3, No 3, pp.278-280 May/June 1996	
		14	Tsimikas, S. et al. In vivo uptake of Radiolabeled MDA2, an oxidation-specific monoclonal antibody provides an accurate measureArterioscler Thromb, Vasc. Biol., Vol 20:689-697.2006	
LYC	-	15	Holovet, P. et al, Monodialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin Invest. Vol 95:2611-9. 1995	

	1 1		
Examiner	Olioa. X. Cork	Date	12/23/05
Signature	, , , , , , , , , , , , , , , , , , , ,	Considered	14-11-0

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting it the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for farm 1449/PTO		Complete if Known			
Substitute for form 14401 10				Application Number	10/705,448
INFORMATION DISCLOSURE				Filing Date	11/11/2003
(Use as many sheets as necessary)			PPLICANT	First Named Inventor	WITZTUM et al
			noenecand	Art Unit	unknown 1641
			loc osbary)	Examiner Name	unknown Ly Cool
Sheet	3	of	3	Attorney Docket Number	6627-P0045C

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LYC	16	Tsimikas S. Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific Mab, identifies native atherosclerotic lesions In vivo. J. Nucl Cardiol. 1999; 6:41-53	
		·	
	1		
		·	

		•		
Examiner	100 m	C-R	Date	12/2/15
Signature	ogwa r	1001 ·	Considered	1425100

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.